Charles Schwab Investment Management Inc Arvinas, Inc. Transaction History

Charles Schwab Investment Management Inc

  • $557 Billion
  • Q2 2025

A detailed history of Charles Schwab Investment Management Inc transactions in Arvinas, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 529,418 shares of ARVN stock, worth $5.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
529,418
Previous 489,239 8.21%
Holding current value
$5.15 Million
Previous $3.43 Million 13.45%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 12, 2025
BUY
$6.07 - $9.62 $243,886 - $386,521
40,179 Added 8.21%
529,418 $3.9 Million
Q1 2025

Sep 15, 2025
SELL
$7.02 - $20.5 $282,056 - $823,669
-40,179 Reduced 7.59%
489,239 $3.43 Million
Q1 2025

May 09, 2025
SELL
$7.02 - $20.5 $329,048 - $960,896
-46,873 Reduced 8.74%
489,239 $3.43 Million
Q4 2024

Feb 06, 2025
BUY
$17.83 - $28.04 $97,048 - $152,621
5,443 Added 1.03%
536,112 $10.3 Million
Q3 2024

Nov 12, 2024
SELL
$23.66 - $32.73 $327,312 - $452,786
-13,834 Reduced 2.54%
530,669 $13.1 Million
Q2 2024

Aug 12, 2024
BUY
$24.46 - $40.4 $402,318 - $664,499
16,448 Added 3.11%
544,503 $14.5 Million
Q1 2024

May 08, 2024
BUY
$36.38 - $52.31 $2.13 Million - $3.06 Million
58,581 Added 12.48%
528,055 $21.8 Million
Q4 2023

Feb 06, 2024
BUY
$14.19 - $42.33 $560,277 - $1.67 Million
39,484 Added 9.18%
469,474 $19.3 Million
Q3 2023

Nov 08, 2023
BUY
$19.64 - $28.21 $1.3 Million - $1.87 Million
66,430 Added 18.27%
429,990 $8.45 Million
Q2 2023

Aug 09, 2023
BUY
$21.73 - $31.43 $102,109 - $147,689
4,699 Added 1.31%
363,560 $9.02 Million
Q1 2023

May 11, 2023
SELL
$26.15 - $37.26 $45,527 - $64,869
-1,741 Reduced 0.48%
358,861 $9.8 Million
Q4 2022

Feb 13, 2023
BUY
$32.47 - $57.24 $249,207 - $439,317
7,675 Added 2.17%
360,602 $12.3 Million
Q3 2022

Nov 14, 2022
BUY
$41.87 - $57.99 $1.32 Million - $1.83 Million
31,587 Added 9.83%
352,927 $15.7 Million
Q2 2022

Aug 15, 2022
SELL
$36.01 - $74.24 $277,601 - $572,316
-7,709 Reduced 2.34%
321,340 $13.5 Million
Q1 2022

May 13, 2022
BUY
$60.27 - $81.57 $479,930 - $649,541
7,963 Added 2.48%
329,049 $22.1 Million
Q4 2021

Feb 11, 2022
BUY
$65.85 - $96.21 $1.27 Million - $1.86 Million
19,316 Added 6.4%
321,086 $26.4 Million
Q3 2021

Nov 16, 2021
BUY
$73.2 - $107.87 $3.78 Million - $5.56 Million
51,589 Added 20.62%
301,770 $24.8 Million
Q2 2021

Aug 16, 2021
BUY
$60.45 - $84.26 $1.17 Million - $1.62 Million
19,279 Added 8.35%
250,181 $19.3 Million
Q1 2021

May 17, 2021
BUY
$58.19 - $91.37 $1.12 Million - $1.76 Million
19,268 Added 9.1%
230,902 $15.3 Million
Q4 2020

Feb 16, 2021
BUY
$20.19 - $84.93 $826,457 - $3.48 Million
40,934 Added 23.98%
211,634 $18 Million
Q3 2020

Nov 13, 2020
BUY
$22.99 - $36.34 $874,079 - $1.38 Million
38,020 Added 28.66%
170,700 $4.03 Million
Q2 2020

Aug 14, 2020
BUY
$29.88 - $56.74 $682,817 - $1.3 Million
22,852 Added 20.81%
132,680 $4.45 Million
Q1 2020

May 15, 2020
BUY
$33.0 - $54.5 $133,584 - $220,616
4,048 Added 3.83%
109,828 $4.43 Million
Q4 2019

Feb 07, 2020
BUY
$15.39 - $44.38 $432,474 - $1.25 Million
28,101 Added 36.18%
105,780 $4.35 Million
Q3 2019

Nov 08, 2019
BUY
$21.55 - $27.61 $265,366 - $339,989
12,314 Added 18.84%
77,679 $1.67 Million
Q2 2019

Aug 09, 2019
BUY
$15.96 - $23.8 $346,475 - $516,674
21,709 Added 49.73%
65,365 $1.44 Million
Q1 2019

May 14, 2019
BUY
$13.55 - $23.79 $12,100 - $21,244
893 Added 2.09%
43,656 $645,000
Q4 2018

Feb 14, 2019
BUY
$11.19 - $18.56 $478,517 - $793,681
42,763 New
42,763 $550,000

Others Institutions Holding ARVN

# of Institutions
245
Shares Held
68.2M
Call Options Held
2.99M
Put Options Held
534K
View Full List

About ARVINAS, INC.

ARVN Quotes by TradingView
  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $517M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email